Civic Intelligence

Human Proteome Organization - Hupo

990EZ • Fiscal year 2013 • EIN 80-0814948

Jan 01, 2013 to Dec 31, 2013

Newton, MA
Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

59th percentile

0.00x

Higher debt load relative to assets than 59% of similar nonprofits.

2013 filings • 501(c)3 • <$500k nonprofits • Source year 2013

Liabilities / Revenue

72nd percentile

0.03x

Higher debt load relative to revenue than 72% of similar nonprofits.

2013 filings • 501(c)3 • <$500k nonprofits • Source year 2013

Net Margin

3rd percentile

-163%

Higher net margin than 3% of similar nonprofits.

2013 filings • 501(c)3 • <$500k nonprofits • Source year 2013

Top Officer Pay

Score unavailable

No value available

This filing does not contain officer compensation rows.

Source year 2013

Asset Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2013

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2013

Assets

$429,279

No earlier filing loaded for comparison.

Net Assets

-

No earlier filing loaded for comparison.

Liabilities

$2,000

No earlier filing loaded for comparison.

Revenue

$68,693

No earlier filing loaded for comparison.

Expenses

$180,750

No earlier filing loaded for comparison.

Net Income

-$112,057

No earlier filing loaded for comparison.

Historical Trend

Balance Sheet Trend

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$1.5M$1.0M$500K$0Assets 2013: $429,279Liabilities 2013: $2,0002013Assets 2014: $484,700Liabilities 2014: $0Net Assets 2014: $484,7002014Assets 2015: $545,908Liabilities 2015: $44,004Net Assets 2015: $501,9042015Assets 2016: $564,459Liabilities 2016: $77,903Net Assets 2016: $486,5562016Assets 2017: $524,266Liabilities 2017: $52,821Net Assets 2017: $471,4452017Assets 2018: $519,959Liabilities 2018: $61,433Net Assets 2018: $458,5262018Assets 2019: $529,195Liabilities 2019: $69,052Net Assets 2019: $460,1432019Assets 2020: $624,533Liabilities 2020: $66,410Net Assets 2020: $558,1232020Assets 2021: $683,130Liabilities 2021: $78,432Net Assets 2021: $604,6982021Assets 2022: $1,100,150Liabilities 2022: $329,574Net Assets 2022: $770,5762022Assets 2023: $1,059,231Liabilities 2023: $81,275Net Assets 2023: $977,9562023Assets 2024: $1,062,343Liabilities 2024: $149,907Net Assets 2024: $912,4362024

Highlighted filing

2013

Assets$429,279
Liabilities$2,000
Net Assets-

Operations Trend

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$2.0M$1.5M$1.0M$500K$0-$500KRevenue 2013: $68,693Expenses 2013: $180,750Net Income 2013: -$112,0572013Revenue 2014: $222,375Expenses 2014: $164,954Net Income 2014: $57,4212014Revenue 2015: $151,800Expenses 2015: $128,984Net Income 2015: $22,8162015Revenue 2016: $147,695Expenses 2016: $163,043Net Income 2016: -$15,3482016Revenue 2017: $140,125Expenses 2017: $155,236Net Income 2017: -$15,1112017Revenue 2018: $161,027Expenses 2018: $173,946Net Income 2018: -$12,9192018Revenue 2019: $169,013Expenses 2019: $167,396Net Income 2019: $1,6172019Revenue 2020: $340,198Expenses 2020: $242,218Net Income 2020: $97,9802020Revenue 2021: $537,131Expenses 2021: $490,556Net Income 2021: $46,5752021Revenue 2022: $1,065,685Expenses 2022: $899,807Net Income 2022: $165,8782022Revenue 2023: $1,547,525Expenses 2023: $1,340,145Net Income 2023: $207,3802023Revenue 2024: $233,025Expenses 2024: $298,545Net Income 2024: -$65,5202024

Highlighted filing

2013

Revenue$68,693
Expenses$180,750
Net Income-$112,057
Filing Detail Status

This 2013 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.

Jump To
Filing Snapshot
Filing Period
Jan 1, 2013 to Dec 31, 2013
Mission and Program Overview

Mission

define and promote proteomics through international cooperation and collaboration in fostering the development of new tecnologies, techniques, and training to better understand human disease

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings